CLINICAL CHARACTERISTICS AND TREATMENT PATTERNS IN CHRONIC KIDNEY DISEASE: REAL-WORLD INSIGHTS FROM ICAREME REGISTRY-JORDAN AND LEBANON COHORT

Introduction:

Chronic kidney disease (CKD) represents a significant global public health challenge, affecting approximately 10% of the world's population.The burden of CKD is particularly pronounced in low- and middle-income countries, where access to healthcare and preventative measures are often limited.

In the Middle East region, the prevalence of CKD is escalating at an alarming rate, driven by high incidence of diabetes, hypertension (HTN), and obesity. Despite these concerning trends, there is a paucity of real-world evidence on CKD management in the region. This knowledge gap hampers the development of tailored interventions and policies addressing CKD local unmet needs. iCaReMe Global Registry (NCT03549754 multinational, prospective, observational study) aims to generate real world data on patients’ characteristics, disease management patterns, health care utilization and outcomes in patients with CKD, type 2 diabetes mellitus (T2DM), HTN, or heart failure (HF).

Methods:

A baseline cross-sectional descriptive analysis was conducted to assess the clinical and demographic characteristics and treatment patterns in CKD patients enrolled from Jordan and Lebanon in iCaReMe Registry between April and December 2022. Descriptive statistics were used to summarize the data. Categorical variables were presented as frequencies and percentages, while continuous variables were summarized using means and standard deviations. Patient data were compared between Jordan and Lebanon using Mann-Whitney U test or Student's t-test for continuous variables and Fisher's Exact test or chi-squared test for categorical variables, as applicable. p value < 0.05 was considered statistically significant. Statistical analyses were conducted using the SAS version 9.4 software (SAS Institute, Inc., Cary, NC, USA)

Results:

In total, 319 adults with CKD were enrolled from 30 sites in Jordan and Lebanon. Mean age was 63 years, BMI was 31.2 kg/m2; 59% were male and 66% had a history of T2DM. The most common etiologies were diabetic kidney disease (76.5%) and hypertensive kidney disease (37.4%). The mean UACR, available for 144 patients (45.1%), was 295 mg/g, while the mean eGFR, reported in 310 patients (97.2%), was 55 ml/min/1.73 m2. The prevalence of KDIGO GFR G3-5 was 61% and albuminuria A2/A3 was 73% (Table 1). Medications included ARBs in 52.7% of patients, ACEi in 16.0%, and SGLT2i in 55.2% (Figure 1). 

Conclusions:

Our results reveal substantial gaps between CKD guidelines and routine clinical practice in Lebanon and Jordan, particularly the underutilization of UACR and the suboptimal application of guideline-directed medical therapy in patients with CKD.

I have potential conflict of interest to disclose.
This Analysis was funded by AstraZeneca part of iCaReMe Registry study sponsored by AstraZeneca. SB, MG, LBK, AF, KJ, HB, AR, HA, AA, RN are study investigators and they received investigators fees. HV and AH are AstraZeneca Employees

I did not use generative AI and AI-assisted technologies in the writing process.